Table 4.
Competing risks regression depicting factors associated with LR following IRE of primary and secondary hepatic metastases. (N=77)
| HR | [95% CI] | p-value | |
|---|---|---|---|
| Body Mass Index | 1.21 | [1.10 - 1.34] | .0001 |
| Ablation Zone Size (cm) | 1.58 | [1.12 - 2.23] | .0093 |
| Other Procedures Performed | 0.30 | [0.08 - 1.06] | 0.06 |
| Pre-IRE Bilirubin | 6.18 | [0.87 - 43.90] | 0.07 |
| Age at Surgery (years) | 0.97 | [0.93 -1.00] | 0.08 |
| Female Gender | 0.60 | [0.11 - 3.31] | 0.56 |
| Elevated Pre-IRE ALP | 0.66 | [0.17 - 2.62] | 0.55 |
| Elevated Pre-IRE ALT | 1.09 | [0.26 - 4.54] | 0.91 |
| High Pre-IRE AST | 1.08 | [0.25 - 4.73] | 0.91 |
| Pre-IRE Albumin | 0.82 | [0.20 - 3.42] | 0.79 |
| Pre-IRE INR | 1.74 | [0.47 - 6.37] | 0.40 |
| Close to Bile Duct | 1.46 | [0.43 - 4.98] | 0.54 |
| Close to Major Vasculature | 0.73 | [0.13 - 3.97] | 0.71 |
| Tumor Size (cm) | 1.35 | [0.88 - 2.07] | 0.17 |
| Tumor Size > 1cm | 2.15 | [0.61 - 7.64] | 0.23 |
| Colorectal Tumor Type | 0.28 | [0.04 - 1.95] | 0.20 |
| # Treatments per Lesion | 1.33 | [0.89 - 1.99] | 0.17 |